“alexion-pharmaceuticals” Archives

in
Entry Author Date Location
J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout 08/19/20 New York
Genentech Gets FDA OK for Injectable Rare Neuroimmune Disease Drug 08/18/20 San Francisco
Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment 06/12/20 National
Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More 05/22/20 National
Rallybio Lands $145M to Alter Course of FNAIT and More Rare Diseases 05/19/20 New York
Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More 05/15/20 National
Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More 05/08/20 National
Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola 05/05/20 Boston
BridgeBio’s Pipeline Expansion Continues as Portfolio’s Milestones Approach 04/30/20 San Francisco
AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics 03/25/20 Europe
Apellis Rare Blood Disease Drug Tops Alexion’s in Head-to-Head Test 01/07/20 Boston
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug 10/31/19 Boston
Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More 10/25/19 National
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More 10/18/19 National
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms 10/16/19 Boston
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma 10/10/19 Boston
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone 09/06/19 National
Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet 08/30/19 Boston
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More 08/23/19 National
The Finalists for the 2019 Xconomy Awards Are … 07/10/19 Boston
Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More 05/10/19 National
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases 04/08/19 Boston
Dyne Therapeutics Emerges With $50M to Take On Rare Muscle Disease 04/03/19 Boston
Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again 02/14/19 National
With Its First Human Data, Solid Slips in Duchenne Gene Therapy Race 02/07/19 Boston
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More 02/01/19 National
Eyeing $500M, Moderna Outlines Plans for Biotech’s Biggest IPO Ever 11/09/18 Boston
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M 10/29/18 Boston
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More 10/26/18 National
Syntimmune Turns Drug For Rare Anemia Into $400M Alexion Buyout 09/26/18 Boston
Page 1 of 4 next page »